You are here

FDA Issues Risk Alert About Bulk Drug Substance Cesium Chloride

Part of an ongoing effort to better oversee use of compounded medications.

In its continuing effort to ensure the safety and efficacy of compounded medications, the FDA yesterday issued a compounding risk alert about cesium chloride, which is sometimes used by cancer patients. The alert, issued to providers and patients, states that “serious adverse events associated with the use of cesium chloride and other cesium salts include abnormal heart rhythms (arrhythmias), low potassium (hypokalemia), seizures, fainting (syncope), cardiac arrest and death.”

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs